2 days ago · Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign the public markets are looking increasingly attractive to drug developers. Eikon …

4 days ago · Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs.

4 days ago · Clinical biopharmaceutical company Eikon Therapeutics on Friday revealed wider nine-month losses in its filing for an initial public offering in the United States.

3 days ago · Eikon, a high-profile startup led by Merck vets, seeks an IPO Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO …

2 days ago · Eikon Therapeutics, a privately held biotechnology company founded by former Merck executives, has taken a decisive step toward the public markets. The high-profile …

All the information you need to install and to download Refinitiv Eikon. Direct link to test if your system can run Refinitiv Eikon.

Eikon Therapeutics is a late-stage clinical biopharmaceutical firm developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.

Eikon Therapeutics filed for an initial public offering. The late-stage clinical biopharmaceutical company didn't disclose in its Friday filing the price or amount of shares it would offer. It ...

1 day ago · Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 million IPO target.

4 days ago · Eikon Therapeutics filed for a Nasdaq IPO after raising $1.1 billion for cancer drugs, led by ex-Amgen and Merck exec Roger Perlmutter.